Which of the following is effective in management of patients of hea failure with preserved ejection fraction?: (A) Digoxin, (B) ARB with neprilysin inhibitor, (C) Isosorbide mononitrate, (D) Phosphodiesterase inhibitor
Answer is B. HFpEF (hea failure with preserved ejection fraction)- A.R.N.I (ARB & Nephrilysin inhibitor) HFrEF (hea failure with reduced ejection fraction)- ACE inhibitor+ Beta Blocker Phosphodiesterase inhibitor: RELAX trial- no improvement in functional capacity, quality of life (QOL), or other clinical and surrogate parameters in patients with HFpEF. Isosorbide mononitrate: (NEAT-HFpEF) trial- no improvement in QOL or submaximal exercise capacity in patients with HFpEF Digoxin Digitalis Investigation Group (DIG) found no role for digoxin in the treatment of HFpEF.